Overview

Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
This study will determine if NXY-059 will reduce functional disability from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strength and coordination.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Disufenton sodium